POA Pharma GmbH, a speciality pharmaceutical company based in Sprockhövel, has announced the winners of its Medical Nutrition Scholarship Award for 2023 as Emilie Göllner and Kim Hamberger.

The award, which was created by POA Pharma’s parent company, Galen Ltd, aims to support people across Europe with metabolic disorders, such as Phenylketonuria (PKU) and Tyrosinemia (TYR), achieve their career goals through further education, training and development courses or apprenticeships.

Speaking on the award, Rens Reinhoudt, POA Pharma GmbH’s Managing Director, stated: “At POA Pharma, our purpose is to be of extraordinary service to our patients, healthcare professionals and partners and so we were thrilled to be able to offer this scholarship to the IMD community. We want to congratulate Kim and Emilie on their success, and we look forward to hearing how the scholarship benefits their studies.”

As part of the scholarship prize, Kim and Emilie will receive a bursary towards their higher education as well as a technology package worth €2,000.

Kim, who studies medicine in Ulm noted: “Due to my illness, it has always been my big dream to study medicine, to help other people and to give something back. But studying takes a long time, is very demanding and without financial support it is a real challenge. Therefore, I am very grateful to have been selected as a winner of this year’s Medical Nutrition scholarship. The financial support and the great technology package will enable me to get the most out of my studies, stay on the ball and ultimately make my dream of becoming a doctor come true.”

Emilie, who is also pursuing a degree in medicine stated: “In addition to the technical equipment that is necessary in any study nowadays, the study of medicine still requires the purchase of many expensive textbooks that are indispensable for the study and the work afterwards. With both, the necessary equipment with digital technology as well as the purchase of the necessary textbooks, the study scholarship will help me immensely.”

To find out more about POA Pharma GmbH and its offering in the German market, including its latest product PKU EASY Microtabs Plus, visit: www.poapharma.de

# ENDS #

About POA Pharma GmbH

POA Pharma GmbH focuses on the distribution, marketing, and commercialisation of proprietary, generic, and rare disease products, bringing German patients selected products and services of POA Pharma Scandinavia AB.

Founded in 2023, it is committed to doing all it can to improve the lives and benefit the health of all generations affected by a variety of diseases.

POA Pharma GmbH benefits from being part of the wider POA Pharma network, providing the resources to help deliver high quality products and services to German patients.

Based in Copenhagen, POA Pharma Scandinavia AB, the parent company of POA Pharma GmbH, works every day to be of value to patients with inborn metabolic diseases (IMDs) and to their caregivers, offering POA products for Phenylketonuria (PKU) as well as for several other IMDs, which are currently available in the UK, Sweden, Norway, Denmark and Finland and the USA.

POA Pharma is part of Galen Limited, a privately owned company established in 1968, with global headquarters in Craigavon, Northern Ireland, and commercial operations based in the UK, Ireland, the Nordics, Europe, and the USA. With global partners in every continent, it is positioned to distribute products worldwide.

Galen Limited was founded in Northern Ireland by the late Sir Allen McClay (d. 2010), the revered philanthropist and entrepreneur, and has since become the proud founding member of the Almac Group

With 6600+ employees and 18 facilities globally, the Almac Group is now owned by the McClay Foundation, whose overarching aim is to make a meaningful improvement and advancement in human health.